Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Altimmune, Inc.NASDAQ: ALT

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 124.46M shares rose 64.7% year over year, ahead of the +37.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 23.7% from the prior quarter. Over 3 fiscal years it compounded at +23.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +64.7% holds above the trailing-twelve-month pace of +37.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
124.46M+23.7% QoQ
Last fiscal yearDec 2025
88.1M+24.1% YoY
LTMMar 2026
98.99M+37.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+64.7%——
1 year+24.1%——
3-year CAGR+23.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
88.1M USD
Year-over-year change
+24.1%
4-year CAGR
+20.9%

Weighted Avg Shares (Diluted) vs competitors

How ALT compares with its peers on the latest reported figures

  • ALT's LTM Mar 2026 weighted avg shares (diluted) of 98.99M shares is the 4th highest of the 9 companies compared; the peer median is 61.08M shares.
  • Its year-over-year change of +37.1% is the 4th highest of 9, against a peer median of +8.7%.
  • Over three fiscal years its annual growth of +23.4% compares with a peer median of +12.8%.
ALT Competitors Peer median
Weighted Avg Shares (Diluted) for ALT and competitors
Company Period LTM YoY 3-year CAGR
ABUSArbutus Biopharma CorporationLTM Mar 2026192.75M +1.8%+8.3%
IVAInventiva S.A.FY2025186.8M +259.4%+65.2%
VIRVir Biotechnology, Inc.LTM Mar 2026140.99M +3.1%+0.9%
ALTAltimmune, Inc.LTM Mar 202698.99M +37.1%+23.4%
GPCRStructure Therapeutics Inc.LTM Jun 202665.7M +14.4%+17.4%
BMEABiomea Fusion, Inc.LTM Mar 202656.46M +55.6%+21.3%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202621.37M +0.6%+1.2%
ASMBAssembly Biosciences, Inc.LTM Mar 202610.86M +66.5%+40.6%
INDPIndaptus Therapeutics, Inc.LTM Mar 20263.96M -56.9%-51.1%
Peer median (excluding ALT) 61.08M+8.7%+12.8%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.41M(68K)426K20K41K
Cost of Revenue00000
Gross Profit4.41M(68K)426K20K41K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development74.54M70.54M65.8M82.23M66.43M
Selling, General & Admin15.41M17.13M18.14M20.97M28.1M
Operating Expenses101.32M87.67M96.36M103.19M94.53M
Depreciation & Amortization551K493K477K238K112K
EBITDA(96.53M)(84.41M)(87.94M)(94.81M)(87.03M)
EBITDA Margin-2189.0%124130.9%-20642.0%-474060.0%-212258.5%
Operating Income(96.91M)(87.74M)(95.93M)(103.17M)(94.49M)
Operating Margin-2197.6%129029.4%-22518.5%-515860.0%-230461.0%
Interest Income203K2.87M7.35M8.07M7.54M
Interest Expense5K8K35K9K1.64M
Other Income / Expenses(176K)2.83M7.48M8.11M5.72M
Income Before Tax(97.09M)(84.91M)(88.45M)(95.06M)(88.77M)
Pre-Tax Margin-2201.6%124867.6%-20762.2%-475295.0%-216522.0%
Income Tax Expense0(197K)00(681K)
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Net Margin-2201.6%124577.9%-20762.2%-475295.0%-214861.0%
EPS (Basic)(2.35)(1.81)(1.66)(1.34)(1.00)
EPS (Diluted)(2.35)(1.81)(1.66)(1.34)(1.00)
Weighted Avg Shares41.28M46.93M53.25M71M88.1M
Weighted Avg Shares (Diluted)41.28M46.93M53.25M71M88.1M

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.